Cardiol Therapeutics Inc. - Class A Common Shares (NQ:CRDL)

1.170 +0.030 (+2.63%)

Delayed Quote Updated: 4:00 PM EDT, Oct 28, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Cardiol Therapeutics Inc. - Class A Common Shares

< Previous 1 2 3 4 Next >

Cardiol Therapeutics Advances CardiolRx in Pivotal Phase III Pericarditis Trial ↗

August 12, 2026

Cardiol Therapeutics (NASDAQ:CRDL) is advancing its synthetic, pharmaceutical-grade cannabidiol formulation, CardiolRx, in a pivotal Phase III trial for recurrent pericarditis, with management...

Via MarketBeat

Phase III Trial Enrollment Reached (75%) for Promising Anti-Inflammatory and Anti-Fibrotic Cardiac Therapies by Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL)

April 29, 2026

Via Get News

Topics Intellectual Property

Correction: Positive Results on MAVERIC Phase 2 and Published ARCHER Study Presented by the Company CEO in Live Interview with Barchart: Cardiol Therapeutics Inc. (NASDAQ: CRDL)

April 27, 2026

Via Get News

Topics Intellectual Property

Why Cardiol Therapeutics (CRDL) Stock Is Down 20% Today ↗

October 09, 2024

Cardiol Therapeutics shares are trading lower by 20% Wednesday morning. The company announced a $13.5 million public offering.

Via Benzinga

$30 Billion Per Year US Heart Failure Market Presents Huge Opportunity for Promising Drugs Advancing with Positive Trial Results for Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL)

April 13, 2026

Via Get News

Topics Intellectual Property

On Tuesday, there are stocks with unusual volume. Let's take a look. ↗

March 31, 2026

Via Chartmill

New Data from the Phase II ARCHER Trial Demonstrate CardiolRx(TM) Improves Heart Structure in Patients with Acute Myocarditis, Supporting Expansion Across Inflammatory Cardiac Conditions

December 01, 2025

(December 1, 2025) - Cardiol Therapeutics Inc. (NASDAQ:CRDL) (TSX:CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company advancing anti-inflammatory and

Via PressReach

New Data from the Phase II ARCHER Trial Demonstrate CardiolRx(TM) Improves Heart Structure in Patients with Acute Myocarditis, Supporting Expansion Across Inflammatory Cardiac Conditions

December 01, 2025

Phase II ARCHER trial showed a significant reduction in left ventricular (LV) mass (p=0.0117) and improvements in multiple key cardiac...

Via Newsfile

Cardiol Therapeutics Announces Topline Results from the Phase II ARCHER Trial of CardiolRx(TM) in Acute Myocarditis

August 06, 2025

(August 6, 2025) - Cardiol Therapeutics Inc. (NASDAQ:CRDL) (TSX:CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on developing anti-inflammatory

Via PressReach

This Visa Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday ↗

June 02, 2025

Via Benzinga

Cardiol Therapeutics Enrolls First Patient in Pivotal Phase III MAVERIC Trial in Recurrent Pericarditis

April 16, 2025

Designed to assess the impact of CardiolRx™ on preventing episodes of recurrent pericarditis, the first patient has been randomized by...

Via Newsfile

InvestorNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) Appoints Terry Lynch to Board, Grants Options

March 27, 2025

Via Investor Brand Network

Cardiol Therapeutics Announces Publication of Research in the Journal of the American College of Cardiology: Basic to Translational Science That Supports Development of Its Proprietary Subcutaneous Drug Candidate, CRD-38, for the Treatment of Heart

February 20, 2025

Toronto, Ontario--(Newsfile Corp. - February 20, 2025) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a...

Via Newsfile

“Cardiol Therapeutics (NASDAQ: CRDL) Heart Health Innovation – AVCO, GXAI, UPC, and More Stocks Driving Groundbreaking Advances”

December 06, 2024

Via AB Newswire

3 Penny Stocks Ready to Break Out in 2025

November 29, 2024

Vuzix, GeoVox Labs, and Cardiol Therapeutics emerged as notable penny stocks late in 2024 for their potential to scale operations and launch new products.

Via MarketBeat

Thanksgiving Week Oversold Stocks to Watch: CRDL, QBTS, PRSO, RGTI & More!

November 25, 2024

Via AB Newswire

“Game-Changers to Watch CRDL, RMSG, WORX, PET and more…Innovative Companies inside”

November 21, 2024

Via AB Newswire

Topics Economy

Cardiol Therapeutics (Nasdaq: CRDL) Advances Orphan Drug Designation for CardiolRx™ at the American Heart Association…more stocks inside…

November 21, 2024

Via AB Newswire

CBD-Based Drug Reduces Pericarditis Pain And Inflammation, Shows New Clinical Study ↗

November 19, 2024

Via Benzinga

Spotlight on Undervalued Nasdaq Stocks: HCWB, CRDL, NIVF, SINT, APLM – A Must-Watch This Week!

November 18, 2024

Via AB Newswire

Cardiol Therapeutics' Phase II MAvERIC-Pilot Clinical Results in Recurrent Pericarditis Presented at the American Heart Association Scientific Sessions 2024

November 18, 2024

Marked and rapid reductions in both pericarditis pain and inflammation maintained throughout the 26-week studyEpisodes of pericarditis per year substantially...

Via Newsfile

“Emerging Innovators Transforming Global Markets: IPA, CRDL, KXIN, GNS, PRSO in Sectors”

November 13, 2024

Via AB Newswire

Topics Electric Vehicles

Biotech and Technology Giants Drive Innovation Across Pharma, Medical Devices, and Industrial Automation CRDL, MODD, CYN

November 07, 2024

Via AB Newswire

“Trump Media (NASDAQ: DJT) Surges on Election Day as SmallCap Stocks CRDL, ALBT, ZVSA, PRSO Emerge”

November 05, 2024

Via AB Newswire

Topics Government

“Top Biotech Opportunities: RVNC, HCTI, GLUE, PRSO, CRDL, Showing Promising Developments”

October 28, 2024

Via AB Newswire

Topics Artificial Intelligence

Healthcare and Biotech Stocks to Watch: MODD, CRDL, DBVT, VRAX

October 23, 2024

Via AB Newswire

Topics Intellectual Property

Cardiol Therapeutics’ (NASDAQ: CRDL) CardiolRx™ Addresses Urgent Medical Condition Myocarditis, a Leading Cause of Sudden Cardiac Death see more stocks inside…

October 22, 2024

Via AB Newswire

AZZ, Helen of Troy And 3 Stocks To Watch Heading Into Wednesday ↗

October 09, 2024

Via Benzinga

“Cardiol Therapeutics (NASDAQ: CRDL) Myocarditis Breakthrough Featured on Fox Business: CardiolRx™ Poised for Medical Impact more stocks inside…”

September 12, 2024

Via AB Newswire

CRDL Stock Earnings: Cardiol Therapeutics Beats EPS for Q2 2024 ↗

August 12, 2024

CRDL stock results show that Cardiol Therapeutics beat analyst estimates for earnings per share the second quarter of 2024.

Via InvestorPlace

< Previous 1 2 3 4 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.